Exploring Quinazoline Nitro-Derivatives as Potential Antichagasic Agents: Synthesis and In Vitro Evaluation
Authors:
- Citlali VázquezCitlali Vázquez
- Audifás-Salvador Matus-MezaAudifás-Salvador Matus-Meza
- Oswaldo Nuñez-MorenoOswaldo Nuñez-Moreno
- Brenda Michelle Barbosa-SánchezBrenda Michelle Barbosa-Sánchez
- Victor Manuel Farías-GutiérrezVictor Manuel Farías-Gutiérrez
- Mariana Mendoza-CondeMariana Mendoza-Conde
- Francisco Hernández-LuisFrancisco Hernández-Luis
- Emma SaavedraEmma Saavedra
Open Access
- 23 September 2024
- Vol. 29 (18) , 4501
Abstract
Trypanosoma cruzi is a protozoan parasite that causes Chagas disease in humans. The current antichagasic drugs nifurtimox and benznidazole have inconveniences of toxicity; therefore, the search for alternative therapeutic strategies is necessary. The present study reports the synthesis, drug-likeness predictions, and in vitro anti-trypanosome activity of a series of 14 quinazoline 2,4,6-triamine derivatives. All compounds were tested against T. cruzi (epimastigotes and trypomastigotes) and in HFF1 human foreskin fibroblasts. The bioassays showed that compounds 2–4 containing nitrobenzoyl substituents at 6-position of the quinazoline 2,4,6-triamine nucleus were the most potent on its antiprotozoal activity. The effect was observed at 24 h and it was preserved for at least 5 days. Also, compounds 2–4 were not toxic to the human control cells, showing high selectivity index. The quinazoline nitro derivatives have potential use as antichagasic agents.Keywords
Funding Information
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (264292, 272941, 282663, CBF-2023-2024-2740)
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (264292, 272941, 282663, CBF-2023-2024-2740)
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (264292, 272941, 282663, CBF-2023-2024-2740)
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (264292, 272941, 282663, CBF-2023-2024-2740)
This publication has 28 references indexed in Scilit:
- Listen to what the animals say: a systematic review and meta-analysis of sterol 14-demethylase inhibitor efficacy for in vivo models of Trypanosoma cruzi infectionParasitology Research, 2024
- Tackling the challenges of human Chagas disease: A comprehensive review of treatment strategies in the chronic phase and emerging therapeutic approachesActa Tropica, 2024
- Molecular Characterization of Four Mexican Isolates of Trypanosoma cruzi and Their Profile Susceptibility to NifurtimoxActa Parasitologica, 2022
- Nitro compounds against trypanosomatidae parasites: Heroes or villains?Bioorganic & Medicinal Chemistry Letters, 2022
- May the epimastigote form of Trypanosoma cruzi be infective?Acta Tropica, 2020
- Design, synthesis and cytotoxic evaluation of quinazoline-2,4,6-triamine and 2,6-diaminoquinazolin-4(3H)-one derivativesMedicinal Chemistry Research, 2018
- Buthionine sulfoximine is a multitarget inhibitor of trypanothione synthesis in Trypanosoma cruziFEBS Letters, 2017
- Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agentsEuropean Journal of Medicinal Chemistry, 2015
- Antileishmanial activity of quinazoline derivatives: Synthesis, docking screens, molecular dynamic simulations and electrochemical studiesEuropean Journal of Medicinal Chemistry, 2015
- Design, synthesis and evaluation of 2,4-diaminoquinazolines as inhibitors of trypanosomal and leishmanial dihydrofolate reductaseBioorganic & Medicinal Chemistry, 2005